Clinical Trials Logo

Radiodermatitis clinical trials

View clinical trials related to Radiodermatitis.

Filter by:

NCT ID: NCT04888234 Not yet recruiting - Clinical trials for Radiation Dermatitis

Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.

Start date: May 8, 2021
Phase: Phase 2
Study type: Interventional

Radiation-induced dermatitis is the most common complication of radiotherapy for cancer treatment. However, there is no satisfactory management to deal with the problem. Ru-Yi-Jin-Huang Powder is one of most common topical TCM drug to treat skin diseases but lack of evidence to support efficacy. The aim of this trial is to evaluate the effectiveness of Ru-Yi-Jin-Huang Powder for radiation-induced dermatitis.

NCT ID: NCT04865731 Recruiting - Clinical trials for Cancer of the Head and Neck

Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

In this study, the study team seek to conduct a pilot clinical study to evaluate the safety and efficacy of a reformulated proton pump inhibitor (PPI) cream (Dermaprazole) in definitive head and neck cancer (HNC) patients.

NCT ID: NCT04851522 Withdrawn - Clinical trials for Radiation Dermatitis

Dilute Bleach Compresses for Radiation Dermatitis

Start date: June 9, 2021
Phase: Early Phase 1
Study type: Interventional

This study is looking at the safety of applying dilute bleach compresses to patients receiving radiation therapy and the impact of these dilute bleach compresses on the frequency and severity of skin changes that occur during radiation therapy. The names of the study interventions involved in this study are: - Di-Dak-Sol: dilute bleach compresses - White petrolatum ointment

NCT ID: NCT04764682 Active, not recruiting - Breast Cancer Clinical Trials

Determining Molecular Drivers of Radiation Dermatitis

Start date: February 21, 2021
Phase:
Study type: Observational

This study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation before overt signs/symptoms appear), and/or treat (post-onset of signs/symptoms) radiation dermatitis (itchy, dry skin or a rash on swollen, reddened skin).

NCT ID: NCT04715386 Terminated - Clinical trials for Radiation Dermatitis

Feasibility in the Prophylaxis of Radiation Dermatitis Severity

Start date: June 22, 2020
Phase:
Study type: Observational

To compare radiation dermatitis severity in irradiated skin protected by an agent verses uncovered skin based on photographs and track patient reported outcomes with use of the agent.

NCT ID: NCT04692389 Withdrawn - Pain Clinical Trials

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Testing the efficacy of the Jalosome® Soothing gel in 2 or 3 grade radiodermatitis healing in oncological patients. The investigators would like to know also the efficacy of the device on quality of life and pain.

NCT ID: NCT04671862 Recruiting - Clinical trials for Head and Neck Cancer

Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.

NCT ID: NCT04630821 Terminated - Clinical trials for Radiation Dermatitis

Utilizing Topical Sodium Hypochlorite to Ameliorate Radiation Dermatitis

Start date: February 8, 2021
Phase: N/A
Study type: Interventional

The objective of the pilot study is to determine compliance, acceptability, and feasibility of using topical sodium hypochlorite to ameliorate or reduce radiation dermatitis, and to collect preliminary data and estimates for planning a larger efficacy study. This 3-week single-arm pilot study will collect information on subject treatment compliance and feedback from subjects (and nurses/subject's treating oncologist) on the acceptability of the use of the treatment. We will also collect data on Common Terminology Criteria for Adverse Events and patient reported outcomes measured using the pain and pruritus PROMIS short-form tools and patient reported outcomes, measured using the Dermatology Life Quality Index (DLQI) tool.

NCT ID: NCT04617730 Not yet recruiting - Radiation Toxicity Clinical Trials

Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.

Start date: January 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The aim is to quantify the efficiency of the Safetac product Mepitel® Film on the prevention of radiodermatitis for cancer patients treated with external beam radiation therapy near the inguinal fold(s). Previous studies have looked into the differences in skin reactions for Mepitel® Film versus hydro-active colloid gel in breast cancer [1, 2] and head and neck cancer [3]. In breast cancer, the prevalence of radiation induced dermatitis has strongly decreased due to of modern radiotherapy techniques and fractionation. In the groin, however, this is not the case, and radiation dermatitis remains an important problem. To the best of our knowledge, no previous study has looked into the efficiency of a prophylactic Mepitel® Film protocol in the inguinal fold. The goal of this study is to evaluate whether the Mepitel® Film offers a lower degree of radiation-induced dermatitis compared to hydro-active colloid gel and thereby challenging the gold standard. References: 1. Herst, P., Bennett, N., Sutherland, A., Peszynski, R., Paterson, D. and Jasperse, M. (2014). Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiotherapy and Oncology, 110(1), pp.137-143. 2. Møller, P., Olling, K., Berg, M., Habæk, I., Haislund, B., Iversen, A., Ewertz, M., Lorenzen, E. and Brink, C. (2018). Breast cancer patients report reduced sensitivity and pain using a barrier film during radiotherapy - A Danish intra-patient randomized multicentre study. Technical Innovations & Patient Support in Radiation Oncology, 7, pp.20-25. 3. Wooding, H., Yan, J., Yuan, L., Chyou, T., Gao, S., Ward, I. and Herst, P. (2018). The effect of Mepitel Film on acute radiation-induced skin reactions in head and neck cancer patients: a feasibility study. The British Journal of Radiology, 91(1081), p.20170298.

NCT ID: NCT04593914 Withdrawn - Clinical trials for Head and Neck Cancer

A Novel Skin Barrier Protectant for Acute Radiodermatitis

CASP-ORL
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Acute radiodermatitis (ARD) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing radiotherapy (RT). To date, there is still no general approved guideline for the prevention and management of acute radiodermatitis. The 3M™ Cavilon™ Advanced Skin Protectant is a novel skin barrier protectant that acts as a physical barrier against abrasion, moisture, and irritants. Moreover, it enables an environment for wound healing. The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the prevention and management of ARD in patients with head and neck cancer.